Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

David J Barnes, Danai Palaiologou, Eleni Panousopoulou, Beate Schultheis, Agnes S M Yong, Alice Wong, Laura Pattacini, John M Goldman, Junia V Melo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia'. Together they form a unique fingerprint.

Keyphrases

Neuroscience

Pharmacology, Toxicology and Pharmaceutical Science